Trial Evaluating Both Tolerability and Improvement for Signs of Facial Photoaging, Discoloration, and Texture in Adult Females of All Skin Types by Combining a Placebo Moisturizer and Non-ablative Laser.
Photoaging
About this trial
This is an interventional treatment trial for Photoaging focused on measuring facial dyschromia
Eligibility Criteria
Inclusion Criteria: Healthy female subjects aged between 25 and 70 years, all skin types included Symmetrical photoaging No known medical conditions that, in the Investigator's opinion may interfere with study participation Willingness to cooperate and participate by following study requirements Female subjects of childbearing potential must be willing to use appropriate contraception method(s) Individuals must sign an informed consent and a photography consent Exclusion Criteria: Subjects that are being treated for cancer or have a history of facial skin cancer on the test areas Subjects with sunburn, moderate to pronounced suntan, pronounced asymmetric skin aging, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might include the test results Subjects currently taking certain medications which in the opinion of the Investigator(s) may interfere with the study. This includes but is not limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids [steroid nose drops, inhalers and/or eye drops are permitted]), and immunosuppessive drugs Subjects with self-reported, uncontrolled systemic disease which, in the opinion of the Investigator, may hinder either the subject's ability to perform all responsibilities of the trial or the Investigator's ability to perform assessments Women known to be pregnant, nursing or planning to become pregnant Subjects participating in other facial clinical studies Subjects who have routinely used an alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks or Retin-A, Retin-A Micro, Renova, Differin, Avita, Tazorac, or Soriatane within 8 weeks of the study start or have taken Isotretinoin within one year of the study start. Subjects who have used Retinol in the last 4 weeks Subjects with current flaring severe inflammatory acne Subjects who have had ablative laser treatments, microneedling, and/or chemical peels or dermabrasion within the last six months Subjects who have had botulinum type-A toxin (e.g. Botox®, Daxxify®, Dysport®, Jeaveau®, or Xeomin®) within the last 6 months Subjects who have had dermal filler injections within the last 12 months Subjects who have had non-ablative laser treatments or IPL within the last 3 months Subjects with known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs Subjects currently using topically applied prescription medications on the face
Sites / Locations
- Austin Institute for Clinical Research, Inc.
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Phyto A+ Brightening Treatment
Placebo Moisturizer
Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts. Product will be topically applied to the assigned side of the face, either left or right side, at Day 0, Day 14, Day 28, Day 42, Day 70, and Day 98.
Placebo Moisturizer will be topically applied to the assigned side of the face, either left or right side, at Day 0, Day 14, Day 28, Day 42, Day 70, and Day 98.